2025-12-12
ENA first public
ERC000011
ENA-CHECKLIST
UOM-BCF
INSDC center name
public
INSDC status
ERS28123313
SRA accession
E-MTAB-16303:WZ4_CADASIL_Control
Submitter Id
ArrayExpress
broker name
iPSC differentiated vascular smooth muscle cell
cell type
not collected
collection date
human
common name
Protocols: CADASIL patient and control iPSCs were differentiated into neural crest-specific VSMCs. Neural crest progenitors were generated by culturing iPSCs on vitronectin-coated plates under defined Essential 6 medium (Gibco; A1516401) with 10 ng/mL FGF2 (PeproTech; 100-18B) and 10 μM SB431542 (Tocris; 1614) that promote neural crest specification. Cells were first passaged at day 5 and subsequently upon reaching confluence, with continued supplementation of FGF2 and SB431542, up to passage 12. After this intermediate stage, cells were dissociated and transferred into SMC differentiation medium composed of Essential 6 supplemented with 10 ng/mL PDGF-BB (PeproTech; 100-14B) and 2 ng/mL TGF-β1 (PeproTech; 100-21) for a minimum of 12 days. Neural crest-derived VSMCs reached maturity by day18, at which point total RNA was isolated from the fully differentiated iPSC-derived VSMCs for RNA-seq analysis. The induced pluripotent stem cells were cultured in Essential 8 Medium (Thermo Fisher Scientific) Total RNA from CADASIL patient and control iPSCs derived neural crest-specific VSMCs was extracted using the RNeasy Mini Kit (Qiagen). Illumina TruSeq Stranded mRNA kit, according to the manufacturer’s protocol.
description
adult
developmental stage
normal
disease
wild type genotype
genotype
not collected
geographic location (country and/or sea)
not applicable
isolate
Homo sapiens
organism
Homo sapiens
organism
skin of body
organism part
Homo sapiens
scientific_name
WZ4_CADASIL_Control
title